Treatment Results of DCLSG Protocol ALL-7
| . | SRG (without protocol II) . | SRT (SRG with protocol II) . | RG . | EG . | All Patients . |
|---|---|---|---|---|---|
| No. of patients | 44 | 30 | 127 | 17 | 218 |
| No CR | 1 | 0 | 1 | 3 | 5 |
| Early death | 1 | 0 | 1 | 0 | 2 |
| No response | 0 | 0 | 0 | 3 | 3 |
| Lost to follow-up | 0 | 0 | 1 | 0 | 1 |
| CR achieved | 43 (98%) | 30 (100%) | 125 (99%) | 14 (82%) | 212 (98%) |
| Death in CR | 0 | 1 | 3 | 2 | 6 |
| Relapses | 19 | 6 | 37 | 1 | 63 |
| During treatment | 6 | 1 | 16 | 1 | 24 |
| After treatment | 13 | 5 | 21 | 0 | 39 |
| Site of relapse | |||||
| BM/blood | 12 | 4 | 26 | 1 | 43 |
| CNS | 5 | 0 | 7 | 0 | 12 |
| BM/CNS | 1 | 0 | 1 | 0 | 2 |
| BM/CNS/testis | 0 | 0 | 1 | 0 | 1 |
| BM/testis | 0 | 1 | 1 | 0 | 2 |
| Testis | 0 | 1 | 1 | 0 | 2 |
| Abdominal mass | 1 | 0 | 0 | 0 | 1 |
| Second malignancy | 0 | 0 | 1 | 1 | 2 |
| In continuous CR | 24 | 23 | 84 | 10 | 141 |
| Patients alive at last follow-up | 33 | 26 | 100 | 11 | 170 |
| Median follow-up | 87 | 71 | 80 | 89 | 79 |
| Range (mo) | 60-105 | 48-82 | 49-110 | 59-103 | 48-110 |
| EFS (% ±SE) | |||||
| At 2 yrs | 72.7 ± 6.7 | 90.0 ± 5.5 | 81.0 ± 3.5 | 63.3 ± 12.0 | 79.2 ± 2.8 |
| At 5 yrs | 54.5 ± 7.5 | 76.7 ± 7.7 | 66.6 ± 4.2 | 63.3 ± 12.0 | 65.3 ± 3.2 |
| No. event-free alive at 5 yrs | 24 | 21 | 78 | 9 | 132 |
| Survival | |||||
| At 2 yrs | 95.5 ± 3.1 | 93.3 ± 4.6 | 89.8 ± 2.7 | 62.5 ± 12.1 | 89.4 ± 2.1 |
| At 5 yrs | 75.0 ± 6.5 | 86.7 ± 6.2 | 80.2 ± 3.6 | 62.5 ± 12.1 | 78.7 ± 2.8 |
| No. alive at 5 yrs | 32 | 24 | 92 | 9 | 157 |
| . | SRG (without protocol II) . | SRT (SRG with protocol II) . | RG . | EG . | All Patients . |
|---|---|---|---|---|---|
| No. of patients | 44 | 30 | 127 | 17 | 218 |
| No CR | 1 | 0 | 1 | 3 | 5 |
| Early death | 1 | 0 | 1 | 0 | 2 |
| No response | 0 | 0 | 0 | 3 | 3 |
| Lost to follow-up | 0 | 0 | 1 | 0 | 1 |
| CR achieved | 43 (98%) | 30 (100%) | 125 (99%) | 14 (82%) | 212 (98%) |
| Death in CR | 0 | 1 | 3 | 2 | 6 |
| Relapses | 19 | 6 | 37 | 1 | 63 |
| During treatment | 6 | 1 | 16 | 1 | 24 |
| After treatment | 13 | 5 | 21 | 0 | 39 |
| Site of relapse | |||||
| BM/blood | 12 | 4 | 26 | 1 | 43 |
| CNS | 5 | 0 | 7 | 0 | 12 |
| BM/CNS | 1 | 0 | 1 | 0 | 2 |
| BM/CNS/testis | 0 | 0 | 1 | 0 | 1 |
| BM/testis | 0 | 1 | 1 | 0 | 2 |
| Testis | 0 | 1 | 1 | 0 | 2 |
| Abdominal mass | 1 | 0 | 0 | 0 | 1 |
| Second malignancy | 0 | 0 | 1 | 1 | 2 |
| In continuous CR | 24 | 23 | 84 | 10 | 141 |
| Patients alive at last follow-up | 33 | 26 | 100 | 11 | 170 |
| Median follow-up | 87 | 71 | 80 | 89 | 79 |
| Range (mo) | 60-105 | 48-82 | 49-110 | 59-103 | 48-110 |
| EFS (% ±SE) | |||||
| At 2 yrs | 72.7 ± 6.7 | 90.0 ± 5.5 | 81.0 ± 3.5 | 63.3 ± 12.0 | 79.2 ± 2.8 |
| At 5 yrs | 54.5 ± 7.5 | 76.7 ± 7.7 | 66.6 ± 4.2 | 63.3 ± 12.0 | 65.3 ± 3.2 |
| No. event-free alive at 5 yrs | 24 | 21 | 78 | 9 | 132 |
| Survival | |||||
| At 2 yrs | 95.5 ± 3.1 | 93.3 ± 4.6 | 89.8 ± 2.7 | 62.5 ± 12.1 | 89.4 ± 2.1 |
| At 5 yrs | 75.0 ± 6.5 | 86.7 ± 6.2 | 80.2 ± 3.6 | 62.5 ± 12.1 | 78.7 ± 2.8 |
| No. alive at 5 yrs | 32 | 24 | 92 | 9 | 157 |